The clinical implication of drug dependency in children and adults with inflammatory bowel disease: A review

Journal of Crohn's and Colitis

Volumn 5, Issue 2, 2011, Pages 81-90

  Duricova, Dana ^a   Pedersen, Natalia ^b   Lenicek, Martin ^a   Jakobsen, Christian ^b   Lukas, Milan ^a   Wewer, Vibeke ^b   Munkholm, Pia ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Corticosteroids; Dependency; Inflammatory bowel disease; Infliximab; Mesalazine; Surgery

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISOLONE;

CLINICAL PRACTICE; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE COURSE; GROUPS BY AGE; HUMAN; INTESTINE SURGERY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; SURGICAL RISK; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHILD; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; SUBSTANCE-RELATED DISORDERS;

EID: 79953091333     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.12.006     Document Type: Review

References (48)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med Aug 8 2002, 347(6):417-429.
2. Langholz E., Munkholm P., Davidsen M., Nielsen O.H., Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol Mar 1996, 31(3):260-266.
3. Munkholm P., Langholz E., Davidsen M., Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol Jul 1995, 30(7):699-706.
4. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut Jun 2006, 55(6):749-753.
5. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut Mar 1994, 35(3):360-362.
6. Tung J., Loftus E.V., Freese D.K., El-Youssef M., Zinsmeister A.R., Melton L.J., et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis Dec 2006, 12(12):1093-1100.
7. Wewer V., Riis L., Vind I., Husby S., Munkholm P., Paerregaard A. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr Jan 2006, 42(1):40-45.
8. de Ridder L., Rings E.H., Damen G.M., Kneepkens C.M., Schweizer J.J., Kokke F.T., et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis Mar 2008, 14(3):353-358.
9. Duricova D., Pedersen N., Lenicek M., Hradsky O., Bronsky J., Adamcova M., et al. Infliximab dependency in children with Crohn's disease. Aliment Pharmacol Ther Apr 1 2009, 29(7):792-799.
10. Duricova D., Pedersen N., Elkjaer M., Slott Jensen J., Munkholm P. 5-Aminosalicylic acid dependency in Crohn's disease: a Danish Crohn colitis database study. J Crohn's Colitis 2010, 4(5):575-581.
11. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology Aug 2001, 121(2):255-260.
12. Chow D.K., Sung J.J., Tsoi K.K., Wong V.W., Wu J.C., Leong R.W., et al. Predictors of corticosteroid-dependent and corticosteroid-refractory inflammatory bowel disease: analysis of a Chinese cohort study. Aliment Pharmacol Ther Apr 15 2009, 29(8):843-854.
13. Franchimont D.P., Louis E., Croes F., Belaiche J. Clinical pattern of corticosteroid dependent Crohn's disease. Eur J Gastroenterol Hepatol Oct 1998, 10(10):821-825.
14. Ho G.T., Chiam P., Drummond H., Loane J., Arnott I.D., Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther Jul 15 2006, 24(2):319-330.
15. Papi C., Festa V., Leandro G., Moretti A., Tanga M., Koch M., et al. Long-term outcome of Crohn's disease following corticosteroid-induced remission. Am J Gastroenterol Apr 2007, 102(4):814-819.
16. Reinisch W., Gasche C., Wyatt J., Moser G., Lochs H., Vogelsang H., et al. Steroid dependency in Crohn's disease. Lancet Apr 1 1995, 345(8953):859.
17. Jakobsen C., Munkholm P., Paerregaard A., Wewer V. Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators-A population-based study. Inflamm Bowel Dis 2010 Dec 3.
18. Vernier-Massouille G., Balde M., Salleron J., Turck D., Dupas J.L., Mouterde O., et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology Oct 2008, 135(4):1106-1113.
19. Gower-Rousseau C., Dauchet L., Vernier-Massouille G., Tilloy E., Brazier F., Merle V., et al. The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol Aug 2009, 104(8):2080-2088.
20. Hyams J., Markowitz J., Lerer T., Griffiths A., Mack D., Bousvaros A., et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol Sep 2006, 4(9):1118-1123.
21. Markowitz J., Hyams J., Mack D., Leleiko N., Evans J., Kugathasan S., et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol Sep 2006, 4(9):1124-1129.
22. Stange E.F., Travis S.P., Vermeire S., Beglinger C., Kupcinkas L., Geboes K., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut Mar 2006, 55(Suppl 1):i1-i15.
23. Stange E.F., Travis S.P.L., Vermeire S., Reinisch W., Geboes K., Barakauskiene A., et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn's Colitis 2008, 2(1):1-23.
24. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet May 4 2002, 359(9317):1541-1549.
25. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med Dec 8 2005, 353(23):2462-2476.
26. Pedersen N., Duricova D., Lenicek M., Elkjaer M., Bortlik M., Andersen P.S., et al. Infliximab dependency is related to decreased surgical rates in adult Crohn's disease patients. Eur J Gastroenterol Hepatol Oct 2010, 22(10):1196-1203.
27. Arnott I.D., McNeill G., Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther Jun 15 2003, 17(12):1451-1457.
28. Hlavaty T., Pierik M., Henckaerts L., Ferrante M., Joossens S., van S.N., et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther Oct 1 2005, 22(7):613-626.
29. Pierik M., Rutgeerts P., Vlietinck R., Vermeire S. Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol Jun 21 2006, 12(23):3657-3667.
30. Bebb J.R., Scott B.B. How effective are the usual treatments for Crohn's disease?. Aliment Pharmacol Ther Jul 15 2004, 20(2):151-159.
31. Caspersen S., Elkjaer M., Riis L., Pedersen N., Mortensen C., Jess T., et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol Nov 2008, 6(11):1212-1217.
32. Ljung T., Karlen P., Schmidt D., Hellstrom P.M., Lapidus A., Janczewska I., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut Jun 2004, 53(6):849-853.
33. Peyrin-Biroulet L., Deltenre P., de S.N., Branche J., Sandborn W.J., Colombel J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol Jun 2008, 6(6):644-653.
34. Kaur N., Mahl T.C. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci Jun 2007, 52(6):1481-1484.
35. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med Oct 11 2001, 345(15):1098-1104.
36. Lees C.W., Ali A.I., Thompson A.I., Ho G.T., Forsythe R.O., Marquez L., et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther Feb 1 2009, 29(3):286-297.
37. Mackey A.C., Green L., Liang L.C., Dinndorf P., Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr Feb 2007, 44(2):265-267.
38. Fidder H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut Apr 2009, 58(4):501-508.
39. Van Moerkercke W., Ackaert C., Jurgens M., Kasran A., Compernolle G., Ballet V., et al. Anti-TNFa induced severe arthralgia as a manifestation of autoimmunity?. Gastroenterology 2010, 138(5):S-60-S-61. Supp1.
40. Louis E., Vernier-Massouille G., Grimaud J., Bouhnik Y., Laharie D., Dupas J., et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 2009, 136(5, Supplement 1):A146.
41. Van Limbergen J., Russell R.K., Drummond H.E., Aldhous M.C., Round N.K., Nimmo E.R., et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology Oct 2008, 135(4):1114-1122.
42. Vind I., Riis L., Jess T., Knudsen E., Pedersen N., Elkjaer M., et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol Jun 2006, 101(6):1274-1282.
43. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology Mar 2007, 132(3):863-873.
44. Travis S.P., Stange E.F., Lemann M., Oresland T., Chowers Y., Forbes A., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut Mar 2006, 55(Suppl 1):i16-i35.
45. Loftus E.V., Kane S.V., Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther Jan 15 2004, 19(2):179-189.
46. Van Staa T.P., Travis S., Leufkens H.G., Logan R.F. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology Jun 2004, 126(7):1733-1739.
47. Dignass A., Van Assche G., Lindsay J.O., Lemann M., Soderholm J., Colombel J.F., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010, 4:28-62.
48. Travis S.P.L., Stange E.F., Lemann M., Oresland T., Bemelman W.A., Chowers Y., et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008, 2:24-62.